证券之星消息，12月15日，生物经济（970038）指数报收于2081.32点，跌1.07%，成交130.04亿元，换 手率1.18%。当日该指数成份股中，上涨的有11家，天康生物以5.76%的涨幅领涨，下跌的有37家，博 腾股份以5.07%的跌幅领跌。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流出合计5.01亿元，游资资金净流出合 计7208.76万元，散户资金净流入合计5.73亿元。成份股资金流向详情见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 生物经济（970038）指数十大成份股详情如下： 近10日内生物经济（970038）指数成份股做了调整，新纳入了9只股票，剔除了9只股票。 ...

Core Points - The Bioeconomy Index (970038) closed at 2087.03 points, down 0.99% with a trading volume of 12.489 billion yuan and a turnover rate of 0.93% [1] - Among the constituent stocks, 10 stocks increased, led by Jingxin Pharmaceutical with a rise of 3.63%, while 40 stocks decreased, with Hualan Biological leading the decline at 3.38% [1] - The net outflow of main funds from the Bioeconomy Index constituents was 0.797 billion yuan, while retail investors saw a net inflow of 0.665 billion yuan [2] Fund Flow - The Bioeconomy Index constituents experienced a net outflow of 0.797 billion yuan from main funds, a net inflow of 0.131 billion yuan from speculative funds, and a net inflow of 0.665 billion yuan from retail investors [2] - In the past 10 days, the Bioeconomy Index constituents underwent adjustments, adding 9 stocks and removing 9 stocks [2]

"绿色铝谷"技术迭代，生物医药成果涌现，"云花""云咖"种业振兴……"十四五"期间，云南以科技创新 为核心引擎，在绿色产业、生物经济、高原农业三大领域多点突破、纵深推进。 从"绿色铝谷"的技术迭代到生物医药的持续领跑，从"云花""云咖"的种业振兴到辐射南亚东南亚的科技 协作……"十四五"期间，云南以科技创新为核心引擎，在绿色产业、生物经济、高原农业三大领域多点 突破、纵深推进。创新之花，正在彩云之南绚丽绽放。 绿色产业引擎强劲 登上文山州砚山县白龙山，俯瞰占地万亩的云南绿色铝创新产业园砚山园区，只见披着幽蓝光伏板的一 座座巨型厂房，呈锁链式布局，串起铝原料—电解铝—铝材精深加工—铝应用—再生铝的全产业循环 链。 这座现代化产业园，绿电使用比例超80%。"链主"企业云南宏泰新型材料有限公司203万吨绿色铝项 目，构建起从阳极炭素到再生铝的全产业链循环体系，项目铝水直供下游企业，节省了大量能源与工艺 设施投入。下游配套28个项目，产品向汽车零部件、大飞机材料领域拓展，高强铝合金产品取得重大技 术突破。 2024年，云南省电解铝产量554万吨，电解铝产能约830万吨，占全国两成，居全国第一位。 "云南在生物医药、生 ...

据哥伦比亚科技部X平台12月3日消息，哥科技部长奥拉亚在第九届"对话 中国"论坛指出，哥方希望同中国加强科技合作。奥拉亚指出，哥方赞叹中国 在量子科学技术领域取得的成就，正与中国在人工智能与量子科学、生物经 济、能源转型、和平建设等多个方面进行合作，并希望推动更多哥科研人员赴 华参加培训。 （原标题：哥科技部长呼吁与中国加强合作） ...

Core Points - The Biotech Economy Index (970038) closed at 2121.91 points, down 0.32%, with a trading volume of 11.12 billion yuan and a turnover rate of 0.9% [1] - Among the index constituents, 17 stocks rose while 32 fell, with Yifan Pharmaceutical leading the gainers at 6.11% and Dean Diagnostics leading the decliners at 2.62% [1] Index Constituents Summary - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (sz300760) with a weight of 12.58% and a market cap of 241.88 billion yuan, down 0.56% [1] - Changchun High-tech (sz000661) with a weight of 4.87% and a market cap of 40.90 billion yuan, up 1.30% [1] - Yishao Dianyi (sz002252) with a weight of 4.74% and a market cap of 44.01 billion yuan, up 0.30% [1] - Kanglong Chemical (sz300759) with a weight of 4.55% and a market cap of 51.28 billion yuan, down 0.55% [1] - Tigermed (sz300347) with a weight of 4.54% and a market cap of 41.59 billion yuan, down 1.02% [1] - Deep Technology (sz000021) with a weight of 4.16% and a market cap of 37.41 billion yuan, down 0.75% [1] - Muyuan Food (sz002714) with a weight of 3.62% and a market cap of 266.58 billion yuan, down 0.67% [1] - Lepu Medical (sz300003) with a weight of 3.19% and a market cap of 29.13 billion yuan, up 0.38% [1] - Aesthetic Care (sz300896) with a weight of 3.16% and a market cap of 43.48 billion yuan, down 0.94% [1] - Yuyue Medical (sz002223) with a weight of 3.07% and a market cap of 36.12 billion yuan, up 0.59% [1] Capital Flow Analysis - The Biotech Economy Index constituents experienced a net outflow of 359 million yuan from institutional investors, while retail investors saw a net inflow of 241 million yuan [3] - Notable capital flows include: - Yifan Pharmaceutical (002019) with a net inflow of 75.07 million yuan from institutional investors [3] - Hualan Biological (002007) with a net inflow of 9.99 million yuan from retail investors [3] - Muyuan Food (002714) with a significant net inflow of 766.06 million yuan from retail investors despite a net outflow of 81.87 million yuan from institutional investors [3] Index Adjustment Summary - Recent adjustments to the Biotech Economy Index included the addition of 9 stocks and the removal of 9 stocks [4] - Newly added stocks include: - Chaoyan Co. (301602) with a market cap of 9.78 billion yuan [4] - Kanghua Biotechnology (300841) with a market cap of 10.63 billion yuan [4] - Yingke Medical (300677) with a market cap of 28.22 billion yuan [4] - Stocks removed from the index include: - Wens Foodstuff Group (300498) with a market cap of 120.30 billion yuan [4] - Hongri Pharmaceutical (300026) with a market cap of 11.08 billion yuan [4]

| 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 12.58% | 200.62 | -0.50% | 2432.40 | > 医药生物 | | sz000661 | 长春高新 | 4.87% | 98.98 | -1.11% | 403.78 | 医药生物 | | sz002252 | 十字典上 | 4.74% | 6.61 | -0.60% | 438.77 | 医药生物 | | sz300759 | 康龙化成 | 4.55% | 29.00 | -2.23% | 515.68 | 医药生物 | | sz300347 | 表格失药 | 4.54% | 48.80 | -3.88% | 420.18 | 医药生物 | | sz000021 | 深科技 | 4.16% | 23.98 | -2.56% | 376.89 | 电子 | | sz002714 | 牧原股份 | 3.62% | 49.13 | -1.15% | 2683.8 ...

Core Insights - The European Commission has officially released a new bioeconomy strategy framework, focusing on "competitiveness + sustainability" as dual core objectives aimed at accelerating the circular economy and decarbonization while reducing dependence on imported fossil fuels [1] - The strategy identifies ten core application areas for bio-based materials and technologies, covering end products such as plastics, textiles, and chemicals, as well as key technological directions like biorefining, advanced fermentation, and permanent storage of biochar [1] - The bioeconomy is seen as a crucial pathway for Europe to enhance economic resilience and replace fossil-based products, supporting 17.1 million jobs and positioning Europe to capture a leading role in the global clean industry [1] Industry Developments - The bioeconomy in the EU has reached a scale of €2.7 trillion in 2023, with expanding application scenarios including bio-based chemicals from algae serving the pharmaceutical and daily chemical sectors, and bio-based plastics gradually replacing traditional materials in packaging and automotive parts [1] - The strategy aims to achieve three goals: enhancing resilience, increasing competitiveness, and protecting the ecosystem, with a commitment to ensuring that natural ecology remains the foundation of economic development [1] Implementation Framework - To unlock potential, the EU has established a three-dimensional implementation system of "regulation + funding + market": simplifying regulatory frameworks to incentivize sustainable business models while ensuring safety, guiding EU finances towards bio-based technologies, and setting demand targets through legislation [2] - The establishment of the "European Bio-based Alliance" aims to facilitate collective procurement of €10 billion in bio-based solutions by 2030 [2] - Industry responses have been positive, with calls for a specialized legal framework and market premium mechanisms for low-carbon products, emphasizing the need for stronger policy guidance to accelerate the commercialization of innovative results [2]

Core Viewpoint - The Biotech Economy Index (970038) closed at 2159.74 points on December 1, with a slight increase of 0.36%, indicating a stable performance in the biotech sector [1]. Group 1: Index Performance - The trading volume for the Biotech Economy Index was 14.616 billion yuan, with a turnover rate of 1.03% [1]. - Among the index constituents, 38 stocks rose, with Nine Strong Bio leading with a 4.43% increase, while 10 stocks fell, with Wens Foodstuffs leading the decline at 2.99% [1]. Group 2: Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price of 201.62 yuan, and a market cap of 244.45 billion yuan [1]. - Changchun High-tech (sz000661) with a weight of 4.87%, latest price of 100.09 yuan, and a market cap of 40.83 billion yuan [1]. - Other notable constituents include Kanglong Chemical (sz300759) and Muping Co. (sz002714) with respective weights of 4.55% and 3.62% [1]. Group 3: Capital Flow - On the same day, the net outflow of main funds from the index constituents totaled 18.3835 million yuan, while retail investors saw a net outflow of 66.8875 million yuan [3]. - Notable capital flows included: - Deep Technology (000021) with a net inflow of 16.216 million yuan from main funds [3]. - Wens Foodstuffs (300498) experienced a net outflow of 50.9861 million yuan from retail investors [3]. Group 4: Index Adjustments - Recent adjustments to the Biotech Economy Index included the addition of 9 new stocks and the removal of 9 stocks [3]. - New additions include: - Super Research Co. (301602) with a market cap of 9.783 billion yuan [4]. - Kanghua Bio (300841) with a market cap of 10.631 billion yuan [4]. - Stocks removed from the index include Wens Foodstuffs (300498) and Jingxin Pharmaceutical (002020) [4].

Core Insights - The 2025 Biomanufacturing Frontier Technology Forum commenced in Harbin, focusing on "Synthetic Biology to Create the Future" as its core theme, aiming to establish a high-end platform for academic discussions, technical exchanges, and industry connections to boost the high-quality development of the biological economy in Heilongjiang [1][2] Group 1: Industry Development - Heilongjiang Province has significant advantages in biomanufacturing, being the largest producer of amino acids and fuel ethanol in China, supported by robust research platforms and industrial clusters [1] - The province is at a critical juncture of "qualitative change" in biomanufacturing, with plans to leverage ecological resource advantages into industrial strengths [1][2] Group 2: Collaboration and Innovation - The forum facilitated knowledge sharing among domestic experts in biomanufacturing, biomedicine, bio-agriculture, and bio-based materials, showcasing the development advantages and innovative outcomes of Heilongjiang's biomanufacturing industry [2] - The event aims to enhance the collaborative development of the biological industry cluster, efficient transformation of scientific achievements, and quality improvement in agriculture, contributing positively to the high-quality development of Heilongjiang's biological economy [2] Group 3: Organizers - The conference was organized by the Heilongjiang Provincial Association for Science and Technology, Heilongjiang Academy of Sciences, and the Microbiology Research Institute of Heilongjiang Academy of Sciences [3]

Core Insights - The event themed "Creating a New Engine for the Development of the Biological Economy in Heilongjiang" highlighted the achievements of Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. (referred to as "Harbin Vaccine") as a leading enterprise in veterinary biological products in Heilongjiang for 63 years, showcasing the synergy of resource endowment, technological reserves, and policy support in the region's biological economy [2] Group 1 - Harbin Vaccine has established a solid innovation foundation through its SPF experimental animal production base and deep collaborations with various research institutions, leading to significant growth in recent years [2] - The company has received 10 new veterinary drug certificates and generated nearly 10 million yuan in technology transfer income, with new product sales exceeding 20 million yuan, covering over 80% of the national market [2] Group 2 - Three key recommendations were proposed to address industry pain points: forming a provincial innovation consortium for veterinary biological products to integrate resources from universities, research institutions, and leading enterprises; establishing a risk warning mechanism for the supply chain; and creating a local supply-demand matching platform to promote the application of local vaccine products in large-scale breeding enterprises [3]